The prevalence of HBV is a major public health concern in China. Patients chronically infected with HBV are at high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
Clarivate Epidemiology’s coverage of neuromyelitis optica spectrum disorder (NMOSD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (China, India,…
Abstract here
Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…
Abstract here
The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected…
DRG Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany,…
Clarivate Epidemiology's coverage of myasthenia gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and…
Clarivate Epidemiology’s coverage of bipolar disorder (BPD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France,…
The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…